Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus versus Advagraf dosing in kidney transplant recipients
2020-001101-22Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in immunocompromise and kidney allograft rejection (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Tacrolimus-LCPT dose to reach adequate trough levels vs Tacrolimus-Extended-Release. Started Jun 2021; status: terminated.
02
Drugs
tacrolimus
03
Conditions
immunocompromisekidney allograft rejection
Beyond the preview
Go deeper on 2020-001101-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001101-22.